Lundbeck's MSA Treatment Gains Orphan Drug Status in Japan
Details : Lu AF82422 (amlenetug) is a alpha-synuclein binder, antibody candidate, which is currently being evaluated for the treatment of multiple system atrophy.
Product Name : Lu AF82422
Product Type : Antibody
Upfront Cash : Inapplicable
March 10, 2025
Lundbeck's Amlenetug Gets FDA Fast Track for Multiple System Atrophy
Details : Lu AF82422 (amlenetug) is a alpha-synuclein binder, antibody candidate, which is currently being evaluated for the treatment of multiple system atrophy.
Product Name : Lu AF82422
Product Type : Antibody
Upfront Cash : Inapplicable
February 12, 2025
Lead Product(s) : Bexicaserin
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bexicaserin PACIFIC OLE Trial Shows Positive 12-Month Results
Details : LP352 (bexicaserin) is a potentially best-in-class & highly selective, oral, 5-HT2C receptor superagonist, which is being evaluated for the treatment of developmental and epileptic encephalopathy.
Product Name : LP352
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 30, 2025
Lead Product(s) : Bexicaserin
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lundbeck Starts Phase 3 Amlenetug Study in Multiple System Atrophy
Details : Lu AF82422 (amlenetug) is a human mAb that binds to extracellular α-synuclein and prevents the uptake and inhibit seeding of aggregation in patients with multiple system atrophy.
Product Name : Lu AF82422
Product Type : Antibody
Upfront Cash : Inapplicable
November 27, 2024
Lead Product(s) : Arimoclomol Citrate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Orphazyme announced that ORARIALS-01 pivotal trial of arimoclomol in amyotrophic lateral sclerosis (ALS) did not meet its primary and secondary endpoints to show benefit in people living with ALS. No important safety signals were reported in the trial.
Product Name : Miplyffa
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 05, 2021
Lead Product(s) : Arimoclomol Citrate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Idalopirdine
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Denovo Biopharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Denovo Biopharma In-Licenses Late-Stage Alzheimer's Disease Asset from Lundbeck
Details : Lundbeck gets options to re-acquire idalopirdine for predetermined undisclosed financial terms, with Denovo and Lundbeck sharing China rights in the event Lundbeck's options are exercised and Denovo retaining all global rights in the event Lundbeck's opt...
Product Name : DB109
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 07, 2021
Lead Product(s) : Idalopirdine
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Denovo Biopharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Arimoclomol Citrate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Orphazyme’s Arimoclomol Receives US Fast Track Designation in Amyotrophic Lateral Sclerosis
Details : Orphazyme has received Fast Track Designation from the US Food and Drug Administration (FDA) for the development of arimoclomol for the treatment of Amyotrophic Lateral Sclerosis (ALS).
Product Name : Miplyffa
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 22, 2020
Lead Product(s) : Arimoclomol Citrate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable